|
4CPS-001 |
EXPERIENCE WITH THE NEW DIRECT ACTING ANTIVIRAL AGENTS IN A THIRD LEVEL HOSPITAL IN 2018 (submitted in 2019) |
|
4CPS-002 |
ANTICHOLINERGIC BURDEN IN CONSTIPATED PATIENT ADMITTED TO AN EMERGENCY DEPARTMENT (submitted in 2019) |
|
4CPS-003 |
LIRAGLUTIDE IN CHRONIC INTESTINAL FAILURE: OVERVIEW AND CASE REPORT (submitted in 2019) |
|
4CPS-004 |
EVALUATION OF THE USE OF HYDROCORTISONE, VITAMIN C AND THIAMINE FOR THE TREATMENT OF SEPTIC SHOCK (submitted in 2019) |
|
4CPS-005 |
RISK FACTORS FOR PERSISTENCE AND TOLERANCE OF COW'S MILK ALLERGY (submitter in 2019) |
|
4CPS-006 |
USE OF AMMONIUM TETRATHIOMOLYBDATE IN WILSON DISEASE (submitted in 2019) |
|
4CPS-007 |
PHARMACEUTICAL CARE AS A MEANS OF PREVENTION AGAINST DRUG IATROGENESIS: CASE OF ORAL ANTICOAGULANTS (submitted in 2019) |
|
4CPS-008 |
RISK FACTORS ASSOCIATED WITH RE-ADMISSION TO THE EMERGENCY DEPARTMENT, IN PATIENTS WITH PREVIOUS GASTROINTESTINAL HAEMORRHAGE SECONDARY TO ORAL ANTICOAGULANT THERAPY (submitted in 2019) |
|
4CPS-009 |
DURATION OF DUAL ANTIPLATELET THERAPY IN CORONARY ARTERY DISEASE: IS PHARMACIST INTERVENTION NECESSARY TO IMPROVE PATIENT SAFETY? (submitted in 2019) |
|
4CPS-010 |
SAFETY AND EFFICACY OF LOW MOLECULAR WEIGHT HEPARINS IN PATIENTS WITH PORTAL VEIN THROMBOSIS (submitted in 2019) |
|
4CPS-011 |
PRESCRIPTION ANALYSIS OF DIRECT ACTING ORAL ANTICOAGULANTS (submitted in 2019) |
|
4CPS-012 |
AUDIT OF ORAL ANTICOAGULANT PRESCRIBING; WHAT HAS CHANGED IN 4 YEARS? (submitted in 2019) |
|
4CPS-013 |
EFFECT OF 2MG INTRAVENOUS PHYTONADIONE TREATMENT ON INTERNATIONAL NORMALISED RATIO IN THE HOSPITALISED ADULT (submitted in 2019) |
|
4CPS-014 |
CLINICAL AND ASSISTED IMPACT OF ISCHAEMICAL ICTUS IN PATIENTS TREATED WITH ORAL ANTICOAGULANTS (submitted in 2019) |
|
4CPS-015 |
SITUATIONAL ANALYSIS OF POSTOPERATIVE IRON SUPPLEMENTATION PRESCRIPTIONS IN A PLASTIC SURGERY DEPARTMENT (submitted in 2019) |
|
4CPS-016 |
INAPPROPRIATE USE OF HUMAN ALBUMIN IN A TEACHING HOSPITAL (submitted in 2019) |
|
4CPS-017 |
EFFICACY AND SAFETY OF TOLVAPTAN IN THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE (submitted in 2019) |
|
4CPS-018 |
EFFICACY OF UREA IN THE TREATMENT OF HYPONATRAEMIA IN SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (submitted in 2019) |
|
4CPS-019 |
ALIROCUMAB AND EVOLOCUMAB: EFFECTIVENESS AFTER 3 YEARS OF FOLLOW-UP IN A REAL WORLD SETTING (submitted in 2019) |
|
4CPS-020 |
USE, EFFICACY AND ADHERENCE TO TREATMENT WITH PCKS9 INHIBITORS IN REAL CLINICAL PRACTICE (submitted in 2019) |
|
4CPS-021 |
ALIROCUMAB AND EVOLOCUMAB: RESULTS IN CLINICAL PRACTICE. (submitted in 2019) |
|
4CPS-022 |
PCSK9 INHIBITORS: EVALUATION OF EFFECTIVENESS IN OUR CENTRE IN RELATION TO THE OFFICIAL CLINICAL ENDPOINTS (submitted in 2019) |
|
4CPS-023 |
LONG-TERM EFFICACY, SAFETY AND ADHERENCE TO ALIROCUMAB IN PATIENTS WITH DYSLIPIDAEMIA FROM A TERTIARY HOSPITAL COHORT (submitted in 2019) |
|
4CPS-024 |
EFFECTIVENESS OF ANTI-INTERLEUKIN-17 DRUGS IN PSORIASIS IN CLINICAL PRACTICE (submitted in 2019) |
|
4CPS-025 |
DUPILUMAB IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS: CASE REPORTS (submitted in 2019) |
|
4CPS-026 |
DALBAVANCIN OFF-LABEL USE: EFFECTIVENESS AND SAFETY (submitted in 2019) |
|
4CPS-027 |
ANTIBIOTIC THERAPY REASSESSMENT AND ITS DOCUMENTATION: CAN VIRTUAL TOOLS IMPROVE PRACTICES? (submitted in 2019) |
|
4CPS-028 |
EXPERIENCE OF CEFTAROLINE USE IN A THIRD LEVEL HOSPITAL (submitted in 2019) |
|
4CPS-029 |
PRELIMINARY RESULTS OF AN ANTIMICROBIAL STEWARDSHIP PROGRAMME IN AN ONCOLOGY DEPARTMENT (submitted in 2019) |
|
4CPS-030 |
INCIDENCE AND RISK FACTORS FOR PROSTHETIC JOINT INFECTION WITHIN 90 DAYS AFTER HEMIARTHROPLASTY FOR FEMORAL NECK FRACTURES IN THE ELDERLY (submitted in 2019) |
|
4CPS-031 |
AUDIT OF ANTIBIOTIC PROPHYLAXIS PRACTICE IN VISCERAL SURGERY IN AN AFRICAN COUNTRY (submitted in 2019) |
|
4CPS-032 |
ANTIBIOTIC PRESCRIPTION THROUGH MOTIVATED REQUEST: CLINICAL PHARMACY TOOL TO IMPROVE APPROPRIATENESS AND LIMIT RESISTANT BACTERIAl STRAINS. A FOLLOW-UP AFTER A YEAR OF MONITORING IN A LOCAL HOSPITAL (submitted in 2019) |
|
4CPS-033 |
OFF-LABEL USE OF NEBULISED AZTREONAM LYSINE IN PATIENTS WITH CHRONIC GRAM-NEGATIVE BACTERIAL LUNG COLONISATION (submitted in 2019) |
|
4CPS-034 |
IS IT POSSIBLE TO RATIONALISE THE ANTIBIOTIC USE AMONG HOSPITALISED PATIENTS BY CLINICAL PHARMACISTS’ ACTIVITY? (submitted in 2019) |
|
4CPS-035 |
CLINICAL PHARMACOKINETICS OF VANCOMYCIN IN NEUTROPENIC PATIENTS (submitted in 2019) |
|
4CPS-036 |
PHARMACEUTICAL INTERVENTIONS IN A SMALL HOSPITAL (submitted in 2019) |
|
4CPS-037 |
CLINICAL OUTCOME IN PAEDIATRIC INTENSIVE CARE UNIT PATIENTS TREATED WITH VANCOMYCIN (submitted in 2019) |
|
4CPS-038 |
STABILITY TO HIGH TEMPERATURES OF THE ANTIMICROBIALS USED IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY PROGRAMMES (submitted in 2019) |
|
4CPS-039 |
NOSOCOMIAL INFECTION BY MULTIRESISTANT PATHOGENS IN KIDNEY TRANSPLANTED PATIENTS (submitted in 2019) |
|
4CPS-040 |
ADEQUACY OF ANTIBIOTIC PRESCRIPTIONS IN A NURSING HOME (submitted in 2019) |
|
4CPS-041 |
PHARMACIST LED ANTIMICROBIAL STEWARDSHIP PROGRAMME (submitted in 2019) |
|
4CPS-042 |
PHARMACIST'S MISSION IN INFECTION MANAGEMENT : EVALUATION OF IMPROVEMENT ACTIONS (submitted in 2019) |
|
4CPS-043 |
EFFECTIVENESS OF A NEW INTERNAL PROTOCOL FOR DOSAGE OF VANCOMYCIN IN NEONATES (submitted in 2019) |
|
4CPS-044 |
THE ROUTINE USE OF ANTIBIOTICS AFTER INSERTION OF A CARDIAC IMPLANTABLE ELECTRONIC DEVICE (CIED): EVIDENCE AND CURRENT PRACTICE (submitted in 2019) |
|
4CPS-045 |
COST EFFECTIVENESS ANALYSIS OF MEROPENEM DOSE OPTIMISATION IN CRITICAL PATIENTS (submitted in 2019) |
|
4CPS-046 |
MONITORING THE PRESCRIPTION OF NEW ANTIBIOTICS: THE WORK OF THE ANTIMICROBIAL STEWARDSHIP TEAM IN A THIRD LEVEL HOSPITAL (submitted in 2019) |
|
4CPS-047 |
ASSESSING THE IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN HOSPITALS: ROLE OF HOSPITAL PHARMACISTS. (submitted in 2019) |
|
4CPS-048 |
BETA-LACTAM ANTIBIOTICS IN CRITICAL ILL PATIENTS: ARE WE DOSING CORRECTLY OUR PATIENTS CORRECTLY? (submitted in 2019) |
|
4CPS-049 |
UNDERDOSING WITH HIGH DOSE PIPERACILLIN/TAZOBACTAM ADMINISTERED VIA CONTINUOUS INFUSION IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY: A STABILITY OR VISCOSITY PROBLEM? (submitted in 2019) |
|
4CPS-050 |
CONFORMITY OF ANTIBIOTIC THERAPY DURATION IN PATIENTS WITH FEBRILE NEUTROPENIA, HOSPITALISED IN THE HAEMATOLOGY DEPARTMENT OF A UNIVERSITY HOSPITAL (submitted in 2019) |
|
4CPS-051 |
ANTIBIOTICS IN THE EMERGENCY DEPARTMENT: IS IT POSSIBLE TO IMPROVE THE PRESCRIPTIONS FOR INFECTIOUS RESPIRATORY DISEASES IN AMBULATORY PATIENTS? (submitted in 2019) |
|
4CPS-052 |
EVALUATION OF PIPERACILIN/TAZOBACTAM DOSAGE IN SEPTIC PATIENTS ATTENDING THE EMERGENCY DEPARTMENT (submitted in 2019) |
|
4CPS-053 |
ANTIMICROBIAL STEWARDSHIP PROGRAMME IN AN INTENSIVE CARE UNIT (submitted in 2019) |
|
4CPS-054 |
A MULTIDISCIPLINARY AND EDUCATIONAL APPROACH TO ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN THE EMERGENCY DEPARTMENT (submitted in 2019) |
|
4CPS-055 |
EVALUATION OF USE, EFFECTIVENESS AND SAFETY OF ISAVUCONAZOL (submitted in 2019) |
|
4CPS-056 |
PROPER USE OF ANTIFUNGALS: IMPLEMENTATION OF OPERATIONAL MULTIDISCIPLINARY TEAMS DEDICATED TO ANTIFUNGALS (submitted in 2019) |
|
4CPS-057 |
THERAPEUTIC DRUG MONITORING OF VORICONAZOLE (submitted in 2019) |
|
4CPS-058 |
MANAGEMENT OF THE HOSPITALISED PATIENT WITH FLU (submitted in 2019) |
|
4CPS-059 |
STRATEGY FOR CHANGE IN ANTIRETROVIRAL THERAPY: LOOKING FOR BETTER RESULTS (submitted in 2019) |
|
4CPS-060 |
PRESCRIPTION ANALYSIS OF TENOFOVIR DISPROXIL FUMARATE AND TENOFOVIR ALAFENAMIDE FUMARATE IN A THIRD LEVEL HOSPITAL (submitted in 2019) |
|
4CPS-061 |
ADHERENCE TO ANTIRETROVIRAL TREATMENT AS A FUNCTION OF THE COMPLEXITY OF THE TREATMENT (submitted in 2019) |
|
4CPS-062 |
PATIENTS WITH DARUNAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE TREATMENT IN A THIRD LEVEL HOSPITAL (submitted in 2019) |
|
4CPS-063 |
USE OF OSELTAMIVIR IN THE TREATMENT OF INFLUENZA A (submitted in 2019) |
|
4CPS-064 |
ADHERENCE TO ANTIRETROVIRAL TREATMENT IN PATIENTS WITH HIV (submitted in 2019) |
|
4CPS-065 |
SWITCHING TO EQUIVALENT ALTERNATIVES: ANTIRETROVIRAL OPTIMISATION STRATEGY (submitted in 2019) |
|
4CPS-066 |
CHANGING FROM COBICISTAT TO A RITONAVIR BOOSTED REGIMEN IN HIV POSITIVE PATIENTS (submitted in 2019) |
|
4CPS-067 |
ANALYSIS OF USAGE OF DIRECT ACTIN ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C. (submitted in 2019) |
|
4CPS-068 |
EFFECTIVENESS OF DOLUTEGRAVIR AND LAMIVUDINE THERAPY IN A TWO DRUG REGIMEN IN A THIRD LEVEL HOSPITAL. (submitted in 2019) |
|
4CPS-069 |
EVALUATION OF PALIVIZUMAB AS PROPHYLAXIS AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION (submitted in 2019) |
|
4CPS-070 |
ANALYSIS OF THE USE OF NON-SPECIFIC INTRAVENOUS IMMUNOGLOBULINS IN A TERTIARY HOSPITAL. (submitted in 2019) |
|
4CPS-071 |
ANALYSIS OF EFFECTIVENESS: USE OF PERTUZUMAB AND TRASTUZUMAB IN NEOADJUVANT TREATMENT IN PATIENTS WITH HER2 POSITIVE BREAST CANCER AND ITS CORRELATION WITH PLASMA LEVELS OF TRASTUZUMAB (submitted in 2019) |
|
4CPS-072 |
COMPARISON OF IMMUNE CHECKPOINT INHIBITORS (NIVOLUMAB, PEMBROLIZUMAB, ATÉZOLIZUMAB AND DURVALUMAB) IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER: TOLERANCE AND FINANCIAL IMPACT (submitted in 2019) |
|
4CPS-073 |
EFFECTIVENESS AND SAFETY OF PLATIN/PERMETREXED COMBINATION IN NON-SMALL CELL LUNG CANCER. (submitted in 2019) |
|
4CPS-074 |
CYCLIN DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER: POTENTIAL DRUG INTERACTIONS (submitted in 2019) |
|
4CPS-075 |
IBRUTINIB ASSOCIATED ATRIAL FIBRILLATION: INCIDENCE AND MANAGEMENT IN THE REAL LIFE CLINICAL SETTING (submitted in 2019) |
|
4CPS-076 |
INDIRECT COMPARISON BETWEEN PEMBROLIZUMAB MONOTHERAPY AND PEMBROLIZUMAB CHEMOTHERAPY REGIMENE IN SQUAMOUS LUNG CANCER (submitted in 2019) |
|
4CPS-077 |
DETECTION AND COMMUNICATION OF CONCOMITANT USE OF CAPECITABINE AND PROTON PUMP INHIBITORS (submitted in 2019) |
|
4CPS-078 |
EFFECTIVENESS AND SAFETY OF ERIBULIN FOR ADVANCED BREAST CANCER TREATMENT (submitted in 2019) |
|
4CPS-079 |
SEQUENCING OF IBRUTINIB, IDELALISIB AND VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPERIENCE IN A TERTIARY HOSPITAL (submitted in 2019) |
|
4CPS-080 |
REAL LIFE TYROSINE KINASE INHIBITOR DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (submitted in 2019) |
|
4CPS-081 |
GEFITINIB IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY. (submitted in 2019) |
|
4CPS-082 |
RISK OF MYELOTOXICITY IN NON-CANCER PATIENTS TREATED WITH CHEMOTHERAPY (submitted in 2019) |
|
4CPS-083 |
SAFETY AND TOLERABILITY OF PALBOCICLIB IN CLINICAL PRACTICE IN A TERTIARY HOSPITAL (submitted in 2019) |
|
4CPS-084 |
ANTHRACYCLINES DOSAGE IN PAEDIATRIC OBESE PATIENTS (submitted in 2019) |
|
4CPS-085 |
IMPROVED ACCESS TO CHEMOTHERAPEUTIC TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA (submitted in 2019) |
|
4CPS-086 |
IMATINIB DOSE OPTIMISATION THROUGH THERAPEUTIC MONITORING IN CHRONIC MYELOID LEUKAEMIA AS PART OF PHARMACEUTICAL CARE (submitted in 2019) |
|
4CPS-087 |
OPTIMISATION OF RESOURCES IN THE USE OF IMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB IN WEIGHT-BASED DOSING INSTEAD OF FLAT DOSE. (submitted in 2019) |
|
4CPS-088 |
CHECKPOINT INHIBITORS IN NON-MICROCYTIC LUNG CANCER: RESULTS IN COMMON CLINICAL PRACTICE (submitted in 2019) |
|
4CPS-089 |
COMPARATIVE EFFECTIVENESS OF NINTEDANIB PLUS DOCETAXEL VERSUS DOCETAXEL MONOTHERAPY IN ADENOCARCINOMA NON-SMALL CELL LUNG CANCER (submitted in 2019) |
|
4CPS-090 |
EFFICACY AND SAFETY OF ERLOTINIB IN NON-SMALL CELL LUNG CANCER (submitted in 2019) |
|
4CPS-091 |
EVALUATION OF AGGRESSIVENESS OF CANCER CARE NEAR THE END OF LIFE IN PATIENTS WITH PANCREATIC CANCER (submitted in 2019) |
|
4CPS-092 |
EVALUATION OF AGGRESSIVENESS OF CANCER CARE NEAR THE END OF LIFE IN PATIENTS WITH METASTATIC NON-MICROCYTIC LUNG CANCER (submitted in 2019) |
|
4CPS-093 |
EFFECTIVENESS OF DEXAMETHASONE MOUTHWASH 0.1MG/ML FOR PREVENTION OF EVEROLIMUS RELATED STOMATITIS (submitted in 2019) |
|
4CPS-094 |
CHARACTERISATION OF POTENTIAL DRUG-DRUG INTERACTIONS IN ONCOLOGICAL PATIENTS TREATED WITH ORAL ANTICANCER DRUGS (submitted in 2019) |
|
4CPS-095 |
REVIEWING THE LATEST CLINICAL RESEARCH FOR TREATING ADVANCED NON-SMALL CELL LUNG CANCER: SELECTION OF RANDOMISED CONTROLLED TRIALS PUBLISHED IN 2018 (submitted in 2019) |
|
4CPS-096 |
EVALUATION OF CLINICAL PHARMACY SERVICES IN A HAEMATOLOGY OUTPATIENT SETTING. (submitted in 2019) |
|
4CPS-097 |
SECOND LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WITH IMMUNE CHECKPOINT INHIBITORS (submitted in 2019) |
|
4CPS-098 |
INDIRECT TREATMENT COMPARISONS OF IBRUTINIB-OBINOTUZUMAB VERSUS VENETOCLAX-OBINOTUZUMAB IN NAIVE CHRONIC LYMPHOCYTIC LEUKAEMIA (submitted in 2019) |
|
4CPS-099 |
REAL WORLD EVIDENCE OF PEMBROLIZUMAB AS MONOTHERAPY IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY STUDY (submitted in 2019) |
|
4CPS-100 |
ANTHRACYCLINE DOSING IN OBESE ADULT PATIENTS: A SYSTEMATIC REVIEW (submitted in 2019) |
|
4CPS-101 |
TRIFLURIDINE-TIPIRACIL FOR METASTATIC COLORECTAL CANCER: REAL WORLD DATA EXPERIENCE (submitted in 2019) |
|
4CPS-102 |
INFLUENCE OF PALBOCICLIB TOXICITY IN THE REAL WORLD CLINICAL PRACTICE (submitted in 2019) |
|
4CPS-103 |
IS THERE A ROLE FOR THE PHARMACIST IN SCREENING FOR METABOLIC SYNDROME? (submitted in 2019) |
|
4CPS-104 |
SWITCHING ORAL ANTIANDROGENIC TREATMENT IN PATIENTS WITH CASTRATE METASTATIC PROSTATE CANCER: AN ANALYSIS. (submitted in 2019) |
|
4CPS-105 |
TOLERANCE PROFILE TO ANTI-THYMOCYTE IMMUNOGLOBULIN TREATMENT AND ITS RELATION TO INFECTIOUS PARAMETERS IN PAEDIATRIC PATIENTS (submitted in 2019) |
|
4CPS-106 |
ANALYSIS OF THE PRESCRIPTION AND SAFE DRUG ADMINISTRATION OF OCRELIZUMAB (submitted in 2019) |
|
4CPS-107 |
IMPACT OF A TOOL IN THE ELECTRONIC CLINICAL HISTORY FOR THE OPTIMISATION OF BIOLOGIC DRUGS IN RHEUMATOLOGY (submitted in 2019) |
|
4CPS-108 |
A REVIEW OF INFLIXIMAB BIOSIMILAR TO BIOSIMILAR SWITCH: REMSIMA TO FLIXABI (submitted in 2019) |
|
4CPS-109 |
ANALYSIS OF CHANGES IN DISEASE MODIFYING TREATMENT IN THE MANAGEMENT OF PATIENTS WITH MULTIPLE SCLEROSIS (submitted in 2019) |
|
4CPS-110 |
VEDOLIZUMAB: OUTCOMES AND THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE (submitted in 2019) |
|
4CPS-111 |
CLINICAL AND ECONOMIC IMPACT OF INFLIXIMAB BIOSIMILAR INFLECTRA IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHROPATHY AND ANKYLOSING SPONDYLITIS NAÏVE AND SWITCHED PATIENTS: AFTER 5 YEARS OF FOLLOW-UP (submitted in 2019) |
|
4CPS-112 |
ADHERENCE TO ADALIMUMAB, GOLIMUMAB AND USTEKINUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE (submitted in 2019) |
|
4CPS-113 |
INOTUZUMAB OZOGAMIZIN FOR THE TREATMENT OF THE RELAPSE B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA IN AN ADULT PATIENT: A CASE REPORT. (submitted in 2019) |
|
4CPS-114 |
BELIEFS ABOUT MEDICATION AND QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH NATALIZUMAB (submitted in 2019) |
|
4CPS-115 |
THERAPEUTIC DRUG MONITORING OF ETANERCEPT BIOSIMILAR IN PSORIATIC PATIENTS (submitted in 2019) |
|
4CPS-116 |
TEN YEARS OF EXPERTISE IN USTEKINUMAB USE FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS (submitted in 2019) |
|
4CPS-117 |
CASE REPORT: USEFULNESS OF THERAPEUTIC DRUG MONITORING OF VEDOLIZUMAB IN MANAGING ACUTE GRAFT VERSUS HOST DISEASE (submitted in 2019) |
|
4CPS-118 |
REAL CLINICAL IMPACT OF DRUG-DRUG INTERACTIONS OF IMMUNOSUPPRESSANTS IN TRANSPLANT PATIENTS. (submitted in 2019) |
|
4CPS-119 |
“REAL WORLD” EXPERIENCE OF TOFACITINIB AND BARICITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: EFFECTIVENESS AND SAFETY EVALUATION (submitted in 2019) |
|
4CPS-120 |
TEN YEAR ANALYSIS OF THE USE OF INFLIXIMAB IN ULCERATIVE COLITIS (submitted in 2019) |
|
4CPS-121 |
EVALUATION OF COST AND EFFICACY OF ECULIZUMAB IN COMPLEMENT MEDIATED THROMBOTIC MICROANGIOPATHY IN THE CLINICAL SETTING (submitted in 2019) |
|
4CPS-122 |
POTENTIAL OPTIMISATION OF TREATMENT WITH USTEKINUMAB IN CROHN'S DISEASE (submitted in 2019) |
|
4CPS-123 |
EVALUATION OF ADHERENCE TO ORAL DISEASE MODIFYING THERAPIES (ORAL-DMT) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (submitted in 2019) |
|
4CPS-124 |
ADHERENCE TO SELECTIVE IMUNOSUPPRESSIVE DRUGS TREATMENTS IN PATIENTS WITH INFLAMMATORY IMMUNE-MEDIATED DISEASES (submitted in 2019) |
|
4CPS-125 |
ACCEPTANCE OF PHARMACOKINETIC RECOMMENDATIONS FOR EVEROLIMUS IN RENAL TRANSPLANT PATIENTS (submitted in 2019) |
|
4CPS-126 |
A POPULATION PHARMACOKINETIC MODEL OF ADALIMUMAB IN A COHORT OF PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWOL DISEASE: A PRELIMINARY ANALYSIS (submitted in 2019) |
|
4CPS-127 |
ECONOMIC IMPACT OF INTENSIFICATION REGIMENS IN INFLAMMATORY BOWEL DISEASE (submitted in 2019) |
|
4CPS-128 |
LIVER TRANSPLANT AND DIABETES MELLITUS (submitted in 2019) |
|
4CPS-129 |
PILOT STUDY TO SURVEY THE ATTITUDE, SUPPLEMENT USE AND STORAGE CONDITIONS OF DRUG PRODUCTS AMONG PATIENTS RECEIVING BIOLOGICAL THERAPY (submitted in 2019) |
|
4CPS-130 |
ONE IN A MILLION: A TNF RECEPTOR-1 ASSOCIATED SYNDROME RESISTANT TO ANTI-TNF-ALPHA THERAPY. (submitted in 2019) |
|
4CPS-131 |
EFFECTIVENESS OF NUSINERSEN IN PAEDIATRIC PATIENTS SMA1 AND SMA2 (submitted in 2019) |
|
4CPS-132 |
INDIRECT TREATMENT COMPARISON OF ANTICALCITONIN GENE RELATED PEPTIDE PATHWAY ANTIBODIES IN CHRONIC MIGRAINE (submitted in 2019) |
|
4CPS-133 |
IS PARACETAMOL A REAL ALTERNATIVE IN THE MANAGEMENT OF PATENT DUCTUS ARTERIOSUS IN PRETERM INFANTS? (submitted in 2019) |
|
4CPS-134 |
PREVALENCE ANALYSIS OF PATIENTS TREATED WITH TRIPTANS AT RISK OF DEVELOPING MEDICATION OVERUSE HEADACHE AND DEVELOPMENT OF A PRESCRIPTION OPTIMISATION STRATEGY. (submitted in 2019) |
|
4CPS-135 |
PERPHENAZINE AND PROPRANOLOL POISONING: A CASE REPORT. (submitted in 2019) |
|
4CPS-136 |
DEXMEDETOMIDINE TREATMENT FOR THE SEDATION OF PRETERM NEONATES (submitted in 2019) |
|
4CPS-137 |
REVIEW OF 3 MONTH PRESCRIPTIONS CONTAINING DRUGS INDUCING QT PROLONGATION AND TORSADE DE POINTE (submitted in 2019) |
|
4CPS-138 |
AN OBSERVATIONAL RETROSPECTIVE STUDY ON TREATMENT ADHERENCE OF LONG ACTING INJECTABLE ANTIPSYCHOTICS (submitted in 2019) |
|
4CPS-139 |
PSYCHOTROPIC DRUG USAGE IN OCTOGENARIAN AND NONAGENARIAN COMPLEX CHRONIC PATIENTS (submitted in 2019) |
|
4CPS-140 |
CURRENT STATUS OF CLINICAL TRIALS FOR ALZHEIMER’S DISEASE (submitted in 2019) |
|
4CPS-141 |
EFFECTIVENESS OF IMMUNOTHERAPY IN SEVERE UNCONTROLLED ASTHMA (submitted in 2019) |
|
4CPS-142 |
EFFECTIVENESS AND SAFETY OF ANTI-IL-5 BIOLOGIC AGENTS IN SEVERE EOSINOPHILIC ASTHMA (submitted in 2019) |
|
4CPS-143 |
TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTION PULMONARY DISEASE: ARE OUR HOSPITAL NURSES AND PHYSICIANS READY TO TREAT AND EDUCATE IN-PATIENTS? (submitted in 2019) |
|
4CPS-144 |
SAFETY AND EFFECTIVENESS OF REDUCED DOSE OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA (submitted in 2019) |
|
4CPS-145 |
EVALUATION OF A PHARMACEUTICAL CARE PROGRAMME FOR PATIENTS BEING TREATED WITH OMALIZUMAB (submitted in 2019) |
|
4CPS-146 |
EFFECTIVENESS AND SAFETY OF OMALIZUMAB IN THE TREATMENT OF SEVERE UNCONTROLLED ASTHMA (submitted in 2019) |
|
4CPS-147 |
THERAPEUTIC POSITIONING AND USE OF INTRAVITREAL RANIBIZUMAB AND AFLIBERCEPT (submitted in 2019) |
|
4CPS-148 |
CLINICAL EVALUATION AND SATISFACTION OF PATIENTS TREATED WITH PRGF-ENDORET (PLASMA RICH IN GROWTH FACTORS) (submitted in 2019) |
|
4CPS-149 |
INITIAL THERAPY FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION: ARE THE GUIDELINES MET IN CLINICAL PRACTICE? (submitted in 2019) |
|
4CPS-150 |
ASSESSMENT OF BURDEN OF DISEASE IN TERMS OF HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (submitted in 2019) |
|
4CPS-151 |
THE IMPACT OF AN INTEGRATED ELECTRONIC MEDICAL RECORD ON THERAPEUTIC DRUG MONITORING (submitted in 2019) |
|
4CPS-152 |
ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN THE EXCHANGE OF THERAPEUTIC EQUIVALENTS (submitted in 2019) |
|
4CPS-153 |
INTENSIFICATION IN BIOLOGICAL TREATMENT IN ULCERATIVE COLITIS (submitted in 2019) |
|
4CPS-154 |
POTENTIALLY INAPPROPRIATE MEDICATION FOR ELDERLY HOSPITALISED PATIENTS IN A TRAUMA AND ORTHOPAEDIC SURGERY DEPARTMENT (submitted in 2019) |
|
4CPS-155 |
REAL LIFE EXPERIENCE OF HOME CARE ADMINISTRATION OF 5-AZACITIDINE AND DOMICILIARY MANAGEMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (submitted in 2019) |
|
4CPS-156 |
ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF DARATUMUMAB IN MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (submitted in 2019) |
|
4CPS-157 |
INTRAVENOUS BIOSIMILAR PRESCRIBING TRENDS IN A THIRD LEVEL SPANISH HOSPITAL (submitted in 2019) |
|
4CPS-158 |
PRESCRIBING TRENDS OF ADALIMUMAB AND ETANERCEPT BIOSIMILAR DRUGS IN A THIRD LEVEL HOSPITAL (submitted in 2019) |
|
4CPS-159 |
MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA AT A TERTIARY CARE TEACHING HOSPITAL (submitted in 2019) |
|
4CPS-160 |
MANAGEMENT OF DRUGS IN PATIENTS WITH SWALLOWING DIFFICULTIES IN A PUBLIC RESIDENTIAL CARE HOME: ROLE OF THE HOSPITAL PHARMACIST (submitted n 2019) |
|
4CPS-161 |
PHARMACIST INTERVENTIONS IN A HOSPITAL AT HOME UNIT (submitted in 2019) |
|
4CPS-162 |
PHARMACEUTICAL INTERVENTIONS IN DRUGS PROVIDED TO THE OUTPATIENT HOSPITAL PHARMACY (submitted in 2019) |
|
4CPS-163 |
CLINICAL PHARMACIST RESIDENCE IN AN INTENSIVE CARE UNIT: SCOPE AND RELEVANCE (submitted in 2019) |
|
4CPS-164 |
A SAFE HANDLING HAZARDOUS DRUGS STRATEGY TO IMPROVE THE SAFETY OF HEALTH PROFESSIONALS: REDUCING EXPOSURE BY MEDICAL PRESCRIPTION REVIEW IN NURSING HOMES (submitted in 2019) |
|
4CPS-165 |
ANALYSIS OF ANTIBIOTIC CONSUMPTION IN A NURSING HOME (submitted in 2019) |
|
4CPS-166 |
ANALYSIS OF THE MAINTENANCE RATE OF LONG ACTING INJECTABLE ANTIPSYCHOTIC TREATMENT IN OUTPATIENTS (submitted in 2019) |
|
4CPS-167 |
EVALUATION OF PHARMACEUTICAL INTERVENTIONS: IMPROVEMENT PLANS (submitted in 2019) |
|
4CPS-168 |
DEVELOPMENT OF A BELGIAN CLASSIFICATION SYSTEM FOR CLINICAL PHARMACY ACTIVITIES (submitted in 2019) |
|
4CPS-169 |
EFFECT OF ABIRATERONE VERSUS ENZALUTAMIDE ON PROSTATE SPECIFIC ANTIGEN LEVELS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (submitted in 2019) |
|
4CPS-170 |
ANALYSIS AND EVALUATION OF PHARMACEUTICAL INTERVENTIONS PERFORMED IN THE EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL (submitted in 2019) |
|
4CPS-171 |
PHARMACISTS AT THE HEALTH CENTRE (submitted in 2019) |
|
4CPS-172 |
OFF-LABEL USE OF INTRALESIONAL CIDOFOVIR IN RECURRENT RESPIRATORY PAPILLOMATOSIS: A CASE REPORT. (submitted in 2019) |
|
4CPS-173 |
ROLE OF THE PHARMACIST IN THE MULTIDISCIPLINARY MANAGEMENT OF OSTEOMYELITIS: FROM MEDICATION RECONCILIATION TO SUPPORT IN CLINICAL DECISION MAKING. (submitted in 2019) |
|
4CPS-174 |
FACILITATORS AND BARRIERS TO PERFORMING COMPREHENSIVE MEDICATION REVIEWS AND FOLLOW-UP IN OLDER HOSPITALISED PATIENTS BY MULTIPROFESSIONAL WARD TEAMS INCLUDING A CLINICAL PHARMACIST (submitted in 2019) |
|
4CPS-175 |
EVOLUTION OF ANTIMICROBIAL CONSUMPTION IN A TRAUMA INTENSIVE CARE UNIT USING DEFINED DAILY DOSES PER 100 OCCUPIED BED DAYS (submitted in 2019) |
|
4CPS-176 |
ELECTROLYTE DISTURBANCES IN PREMATURE INFANTS WITH INTRAUTERINE GROWTH RESTRICTION RECEIVING PARENTERAL NUTRITION (submitted in 2019) |
|
4CPS-177 |
COMPARATIVE STUDY OF PATIENT PROFILES AND INITIAL ANTIRETROVIRAL TREATMENT IN 2014 VERSUS 2018 (submitted in 2019) |
|
4CPS-178 |
TRANSCRIPTION OF SUPPORTIVE MEDICATION FOR INPATIENT CHEMOTHERAPY BY DESIGNATED ONCOLOGY WARD PHARMACISTS (submitted in 2019) |
|
4CPS-179 |
THE WIDE REVIEW OF POLYPHARMACY IN THE FRAIL OLDER PERSON (submitted in 2019) |
|
4CPS-180 |
FROM EVIDENCE BASED MEDICINE TO PRACTICE: GUM CHEWING FOR POSTOPERATIVE RECOVERY OF GASTROINTESTINAL FUNCTION AFTER COLORECTAL SURGERY WITH INTERPROFESSIONAL TEAMWORK (submitted in 2019) |
|
4CPS-181 |
BUDGETARY IMPACT OF BIOSIMILAR PRESCRIPTION IN THE TREATMENT OF RHEUMATIC DISEASES (submitted in 2019) |
|
4CPS-182 |
PRELIMINARY DESIGN OF HOSPITAL TELEPHARMACY (submitted in 2019) |
|
4CPS-183 |
SELECTION OF A POPULATION PHARMACOKINETIC MODEL OF ADALIMUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE SUITABLE FOR THERAPEUTIC DRUG MONITORING (submitted in 2019) |
|
4CPS-184 |
EVALUATION OF A CLINICAL PHARMACY SERVUCE ON AN INPATIENT WARD IN AN ACUTE HOSPITAL (submitted in 2019) |
|
4CPS-185 |
ADMINISTRATION OF ORAL ANTICANCER DRUGS FOR PATIENTS WITH SWALLOWING DIFFICULTIES (submitted in 2019) |
|
4CPS-186 |
DESCRIPTION OF PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT (submitted in 2019) |
|
4CPS-187 |
PROGNOSTIC VALUE OF HAEMATOLOGICAL INFLAMMATORY MARKERS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER TREATED WITH PEMBROLIZUMAB (submitted in 2019) |
|
4CPS-188 |
PHARMACEUTICAL INTERVENTION TO REDUCE THE ANTICHOLINERGIC BURDEN IN OLDER HOSPITALISED PATIENTS (submitted in 2019) |
|
4CPS-189 |
FALL INCIDENTS IN NURSING HOME PATIENTS: DEVELOPMENT OF A PREDICTIVE CLINICAL RULE (FINDER) (submitted in 2019) |
|
4CPS-190 |
EVALUATION OF A NEW CLINICAL PHARMACY SERVICE WITHIN A NEWLY LAUNCHED SURGICAL ADMISSION PROCESS (submitted in 2019) |
|
4CPS-191 |
PHARMACEUTICAL INTERVENTIONS IN A MEDICATION RECONCILIATION PROGRAMME UPON ADMISSION IN SURGICAL PATIENTS (submitted in 2019) |
|
4CPS-192 |
ESTIMATING THE SURVIVAL PROGNOSIS OF PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCY ON HOME PARENTERAL NUTRITION: A RETROSPECTIVE, MONOCENTRE STUDY (submitted in 2019) |
|
4CPS-193 |
MEASURING THE IMPACT OF HOSPITAL PHARMACIST PRESCRITION REVIEWING IN AN ONCOLOGY SETTING ON THE PHARMACOVIGILANCE REPORTING IN A COMPREHENSIVE CANCER CENTRE (submitted in 2019) |
|
4CPS-194 |
THE UNDERREPORTING RATE AS A PHARMACOVIGILANCE PROCESS INDICATOR IN A COMPREHENSIVE CANCER CENTRE (submitted in 2019) |
|
4CPS-195 |
PHARMACEUTICAL INTERVENTIONS IN PARENTERAL NUTRITION FOR CRITICALLY ILL PATIENTS (submitted in 2019) |
|
4CPS-196 |
STABILITY OF LIPID EMULSION IN PAEDIATRIC PARENTERAL NUTRITION WITH HIGH ELECTROLYTIC LOAD (submitted in 2019) |
|
4CPS-197 |
MONITORING OF OFF-LABEL USE: ANALYSIS OF PRESCRIPTIONS IN THE PHARMACY'S ANTIBLASTIC DRUGS UNIT (submitted in 2019) |
|
4CPS-198 |
RESULTS OF A MEDICATION RECONCILIATION PROGRAMME IN COMPLEX CHRONIC PATIENTS AT HOSPITAL DISCHARGE (submitted in 2019) |
|
4CPS-199 |
PHARMACEUTICAL INTERVENTIONS IN HAEMODIALYSIS PATIENTS: A 2 YEAR OVERVIEW (submitted in 2019) |
|
4CPS-200 |
DIFFERENCES IN ALLELIC FREQUENCIES OF RELEVANT PHARMACOGENETIC POLYMORPHISMS MAY LEAD TO LOCAL GENE PANEL DEVELOPMENT (submitted in 2019) |
|
4CPS-201 |
IDENTIFICATION OF HAZARDOUS DRUGS AND PROCESS IN A UNIVERSITY HOSPITAL (submitted in 2019) |
|
4CPS-202 |
NUTRITIONAL RISK EVALUATION IN INSTITUTIONALISED ELDERLY PATIENTS IN A PUBLIC NURSING HOME (submitted in 2019) |
|
4CPS-203 |
NURSES: WHAT DO YOU THINK ABOUT A PHARMACEUTICAL PRESENCE IN THE EMERGENCY WARD? (submitted in 2019) |
|
4CPS-204 |
MEDICINE RECONCILIATION AT HOSPITAL DISCHARGE (submitted in 2019) |
|
4CPS-205 |
ASSESSMENT OF THE PALATABILITY OF ANTIBIOTIC ORAL SUSPENSIONS: A LITERATURE REVIEW. (submitted in 2019) |
|
4CPS-206 |
IMPACT OF MEDICATION RECONCILIATION IN COMPLEX CHRONIC PATIENTS (submitted in 2019) |
|
4CPS-207 |
TREATMENT ADEQUACY IN DOMICILIARY CARE PROGRAMME PATIENTS (submitted in 2019) |
|
4CPS-208 |
NUTRITIONAL SUPPORT IN ONCOLOGY: A CROSS SECTIONAL STUDY AMONG CANCER PATIENTS (submitted in 2019) |
|
4CPS-209 |
AN EXPLORATION INTO A PHARMACIST-LED MEDICINES RECONCILIATION SERVICE IN AN ACUTE HOSPITAL SETTING. (submitted in 2019) |
|
4CPS-210 |
PHARMACISTS’ COMMUNICATION WITH FOREIGN LANGUAGE SPEAKING PATIENTS IN A FOREIGNER SETTLEMENT AREA, JAPAN (submitted in 2019) |
|
4CPS-211 |
ADHERENCE AND INTERACTIONS IN PATIENTS TREATED WITH ABIRATERONE AND ENZALUTAMIDE (submitted in 2019) |
|
4CPS-212 |
HEALTHCARE PROVIDERS' VIEWS OF PHARMACY TEAM INVOLVEMENT IN THE PREPARATION AND ADMINISTRATION OF MEDICINES ON INPATIENTS WARDS: AN EXPLORATORY STUDY (submitted in 2019) |
|
4CPS-213 |
PATIENT PERCEPTIONS OF GENERIC MEDICINES 20 YEARS AFTER THE RIGHT OF SUBSTITUTION BY PHARMACISTS (submitted in 2019) |
|
4CPS-214 |
IMPROVING INTRAVENOUS TO ORAL SWITCH BY IDENTIFYING AND TACKLING BARRIERS PERCEIVED BY PHYSICIANS AND NURSES (submitted in 2019) |
|
4CPS-215 |
THE IMPACT OF CLINICAL PHARMACIST DRIVEN INTERVENTIONS ON PATIENT SAFETY IN HOSPITALISED PATIENTS: PRELIMINARY RESULTS OF A POINT PREVALENCE STUDY (submitted in 2019) |
|
4CPS-216 |
PROMOTION OF THE QUALITY OF DRUG EDUCATION FOR THE PATIENTS USING NASOGASTRIC TUBE FEEDING BEFORE DISCHARGE (submitted in 2019) |
|
4CPS-217 |
NETUPITANT-PALONOSETRON IN BREAST CANCER: POTENTIAL DRUGS INTERACTIONS |
|
4CPS-218 |
ANTIDIABETIC TREATMENT IN FRAIL PATIENTS WITH TYPE II DIABETES ADMITTED TO THE EMERGENCY DEPARTMENT FOR ALTERED GLYCAEMIA |
|
4CPS-219 |
COMPARISON OF THE NUMBER OF PARENTAL NUTRITION PRESCRIPTIONS IN 2020 DURING THE COVID-19 PANDEMIC WITH THE SAME TIME PERIOD IN 2019 |
|
4CPS-220 |
PATIENT SATISFACTION WITH PHARMACIST EDUCATION ON ORAL ANTICOAGULANT MEDICATION |
|
4CPS-221 |
EFFECT OF SARS-CoV-2 PANDEMIC ON DIRECT ORAL ANTICOAGULANTS USE IN THE PRIMARY CARE SETTING |
|
4CPS-222 |
CONCORDANCE BETWEEN GUIDELINES ON PERIOPERATIVE MANAGEMENT OF NOVEL ORAL ANTICOAGULANTS AND ITS IMPLEMENTATION AND PREVENTABLE CAUSES OF THE OCCURRENCE OF ISCHAEMIC STROKE |
|
4CPS-223 |
REAL WORLD EXPERIENCE OF SELEXIPAG FOR PULMONARY ARTERIAL HYPERTENSION |
|
4CPS-224 |
THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS: ASSESSMENT OF THE CURRENT PRACTICES IN A 950 BED HOSPITAL GROUP |
|
4CPS-225 |
IMPLEMENTATION OF A COMPUTER ALGORITHM IN THE ELECTRONIC HEALTH RECORD TO IDENTIFY INPATIENTS WITH UNTREATED ATRIAL FIBRILLATION TO OPTIMISE STROKE PREVENTION |
|
4CPS-226 |
EFFECTIVENESS OF CARBOXYMALTOSE IRON IN PREOPERATIVE ANAEMIA TREATMENT |
|
4CPS-227 |
HUMAN SERUM ALBUMIN: ANALYSIS OF USE |
|
4CPS-228 |
VERNAKALANT VERSUS FLECAINIDE FOR CONVERSION OF RECENT ONSET ATRIAL FIBRILLATION IN PATIENTS ATTENDING THE EMERGENCY DEPARTMENT |
|
4CPS-229 |
ANALYSIS OF CLINICAL PHARMACIST INTERVENTIONS IN THE HEART FAILURE DAY HOSPITAL. |
|
4CPS-230 |
ANTIARRHYTHMIC THERAPY EVALUATION IN A HOSPITAL SETTING |
|
4CPS-231 |
REAL WORLD DATA OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF HYPERLIPIDAEMIA: ANALYSIS 3 YEARS AFTER INTRODUCTION IN CLINICAL PRACTICE |
|
4CPS-232 |
USE OF DUPILUMAB IN THE TREATMENT OF ATOPIC DERMATITIS IN REAL CLINICAL PRACTICE |
|
4CPS-233 |
HOME MANAGEMENT OF ACUTE MULTIPLE SCLEROSIS OUTBREAK: ADAPTATION TO CORONAVIRUS PANDEMIC |
|
4CPS-234 |
GLUCOCORTICOID INDUCED HYPERGLYCAEMIA IN NON-DIABETIC PATIENTS IN AN EMERGENCY DEPARTMENT |
|
4CPS-235 |
SYSTEMIC CORTICOSTEROIDS IN THE TREATMENT OF SARS-CoV-2 INFECTION |
|
4CPS-236 |
USE OF ETELCALCETIDE IN PATIENTS UNDERGOING HAEMODIALYSIS |
|
4CPS-237 |
FEASIBILITY OF CONTINUOUS ADMINISTRATION OF ANTIMICROBIALS IN HOSPITAL: NOTHING IS EVER AS IT SEEMS? |
|
4CPS-238 |
EVALUATION OF EFFECTIVENESS OF COMPOUNDED ORAL VANCOMYCIN CAPSULES FOR TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION |
|
4CPS-239 |
THERAPEUTIC DRUG MONITORING OF GENTAMICIN IN NEONATES |
|
4CPS-240 |
THERAPEUTIC MONITORING OF VANCOMYCIN IN A COHORT OF PAEDIATRIC PATIENTS |
|
4CPS-241 |
IMPACT OF ANTIBIOTIC PRESCRIBING IN AN EMERGENCY DEPARTMENT ON HOSPITAL STAYS, READMISSION AND MORTALITY |
|
4CPS-242 |
ACUTE RESPIRATORY INFECTIONS: AN ANALYSIS OF HOSPITAL ANTIBIOTHERAPY PRESCRIPTION QUALITY FOR THE PAEDIATRIC POPULATION |
|
4CPS-243 |
HEALHCARE ASSOCIATED CLOSTRIDIOIDES DIFFICILE INFECTION IN SURGICAL AND MEDICAL PATIENTS |
|
4CPS-244 |
THERAPEUTIC DRUG MONITORING GUIDED PHARMACY INTERVENTIONS TO OPTIMISE THE DOSAGE OF BETA-LACTAMS ADMINISTERED IN CONTINUOUS INFUSION IN NON-CRITICALLY ILL PATIENTS. |
|
4CPS-245 |
DURATION OF ANTIBIOTIC TREATMENT IN PATIENTS DISCHARGED FROM A SHORT STAY HOSPITALISATION UNIT |
|
4CPS-246 |
CORONAVIRUS FIRST WAVE EFFECT ON ANTIBIOTIC CONSUMPTION AND ANTIMICROBIAL RESISTANCE |
|
4CPS-247 |
VARIATIONS IN CONSUMPTION OF ANTIMICROBIALS IN INTERNAL MEDICINE WARDS OF HOSPITALS |
|
4CPS-248 |
APPROPRIATENESS OF THE CLOSTRIDIUM DIFFICILE INFECTION PRESCRIPTION PRIOR TO THE IMPLEMENTATION OF A PROTOCOL FOR ITS MANAGEMENT |
|
4CPS-249 |
SECOND GENERATION β-LACTAM/ β-LACTAMASE INHIBITOR COMBINATIONS: CEFTAZIDIME-AVIBACTAM AND CEFTOLOZANE-TAZOBACTAM EXPERIENCE OF USE |
|
4CPS-250 |
EVALUATION OF PRESCRIPTION ADEQUACY TO THE ANTIBIOTHERAPY PROTOCOL IN INTRA-ABDOMINAL INFECTION IN A REGIONAL HOSPITAL |
|
4CPS-251 |
EVALUATION OF CLOSTRIDIUM DIFFICILE INFECTION MANAGEMENT PRIOR TO IMPLEMENTATION OF A PROTOCOL FOR IMPROVEMENT |
|
4CPS-252 |
STUDY OF THE IMPLEMENTATION OF A VANCOMYCIN PHARMACOKINETIC MONITORING PROGRAMME IN PAEDIATRICS |
|
4CPS-253 |
THE IMPORTANCE OF THE PHARMACOKINETIC PROFILE IN PATIENTS WITH ULTRA-RARE DISEASES:A CASE REPORT |
|
4CPS-254 |
A RETROSPECTIVE STUDY OF ANTIMICROBIAL STEWARDSHIP IN A UNIVERSITY HOSPITAL |
|
4CPS-255 |
CLINICAL EXPERIENCE OF CEFTAROLINE USE IN A THIRD LEVEL HOSPITAL |
|
4CPS-256 |
HEPATITIS C RETREATMENT OF A PATIENT WHO FAILED MULTIPLE TREATMENTS INCLUDING PROTEASE INHIBITOR AND NON-STRUCTURAL PROTEIN 5A INHIBITORS: A CASE REPORT |
|
4CPS-257 |
RELEVANCE OF RITONAVIR INTERACTIONS IN HIV TREATMENTS THAT INVOLVE TREATMENT MODIFICATION |
|
4CPS-258 |
EVALUATION OF MEDICINES ADHERENCE AND ASSOCIATED FACTORS IN PATIENTS WITH CHRONIC HEPATITIS B |
|
4CPS-259 |
ONE YEAR WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE |
|
4CPS-260 |
ANALYSIS OF DRUGS INTERACTIONS BETWEEN CORONAVIRUS (COVID-19) ANTIVIRAL TREATMENT AND CONCOMITANT MEDICATION |
|
4CPS-261 |
USE OF INTRAVENOUS IMMUNOGLOBULIN: BY THE BOOK? |
|
4CPS-262 |
CLINICAL EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN NEUROLOGY: A RETROSPECTIVE COHORT STUDY AT THE MATER MISERICORDIAE UNIVERSITY HOSPITAL |
|
4CPS-263 |
CASE REPORT OF KAWASAKI DISEASE AND SARS-COV-2 INFECTION IN A PAEDIATRIC HOSPITAL |
|
4CPS-264 |
AUTOIMMUNE MYOPATHY RESULTING FROM A THERAPY WITH NIVOLUMAB FOR METASTATIC NON-SMALL CELL LUNG CANCER: A CASE REPORT |
|
4CPS-265 |
CEMIPLIMAB FOR THE TREATMENT OF RELAPSE OF A CUTANEOUS SQUAMOUS CELL CARCINOMA IN AN ADULT PATIENT: A CASE REPORT |
|
4CPS-266 |
AFATINIB AS FIRSTLINE TREATMENT FOR ADVANCED LUNG ADENOCARCINOMA IN A PATIENT HARBOURING EXON 19 DELETION IN EGFR: A CASE REPORT |
|
4CPS-267 |
RETROSPECTIVE ANALYSIS OF CARBOPLATIN DOSING PRESCRIBED IN A CHEMOTHERAPY REGIMEN AND ITS RELATIONSHIP WITH TOXICITY |
|
4CPS-268 |
NIVOLUMAB VERSUS PEMBROLIZUMAB IN SECONDLINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER IN CLINICAL PRACTICE |
|
4CPS-269 |
HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY ASSOCIATED WITH CYTOREDUCTIVE SURGERY IN PERITONEAL CANCER TREATMENTS: A MULTIDISCIPLINARY EXPERIENCE TO EVALUATE ITS EFFICACY |
|
4CPS-270 |
RESULTS OF EFFECTIVENESS AND SAFETY IN REAL CLINICAL PRACTICE OF NIVOLUMAB, PEMBROLIZUMAB AND ATEZOLIZUMAB IN NON-SMALL CELL LUNG CANCER |
|
4CPS-271 |
EVALUATION OF THE EFFICACY OF ANTI-PD-L1 IMMUNOTHERAPY IN NON-MICROCRITICAL LUNG CANCER IN CLINICAL PRACTICE |
|
4CPS-272 |
PHARMACIST ROLE IN HEALTH OUTCOME OF VD-PACE SAVAGE REGIMEN IN AN ADULT FEMALE PATIENT WITH RARE RELAPSED AND REFRACTORY IgD LAMBDA MULTIPLE MYELOMA |
|
4CPS-273 |
DOES AGE REALLY MATTERS ON THE PREVALENCE OF DRUG-DRUG INTERACTIONS WITH ENDOVENOUS CHEMOTHERAPY? |
|
4CPS-274 |
REAL WORLD EFFECTIVENESS OF PALBOCICLIB AND RIBOCICLIB IN WOMEN WITH METASTATIC BREAST CANCER. |
|
4CPS-275 |
EFFICACY AND SAFETY OF TRIFLURIDINE/TIPIRACIL IN PATIENTS WITH METASTATIC COLORECTAL CANCER: REAL WORLD DATA |
|
4CPS-276 |
ATEZOLIZUMAB IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY REAL WORLD DATA STUDY. |
|
4CPS-277 |
CETUXIMAB VERSUS BEVACIZUMAB IN METASTATIC COLORECTAL CANCER: A COMPARATIVE EFFECTIVENESS AND PATIENT REPORTED OUTCOMES MULTI-COHORT STUDY |
|
4CPS-278 |
EFFECTIVENESS AND SAFETY OF CISPLATIN PLUS GEMCITABINE IN METASTATIC BREAST CANCER |
|
4CPS-279 |
CANCER PAIN MANAGEMENT APPROACH CONSIDERING POTENTIAL DRUG INTERACTIONS IN PATIENTS RECEIVING ORAL ANTITUMOUR TREATMENT |
|
4CPS-280 |
BENEFITS OF PHARMACOKINETIC ESTIMATION OF METHOTREXATE LEVELS IN PAEDIATRIC OSTEOSARCOMA PATIENTS |
|
4CPS-281 |
HIGH DOSE METHOTREXATE IN PEDIATRIC OSTEOSARCOMA PATIENTS: EFFECTIVENESS AND SAFETY. |
|
4CPS-282 |
EPIDEMIOLOGY AND CLINICAL COURSE OF PATIENTS WITH CANCER DIAGNOSED WITH SARS-COV-2 INFECTION |
|
4CPS-283 |
ONCOHAEMATOLOGICAL PHARMACEUTICAL CARE CONSULTATION. IS THE INFORMATION ON THE EUROPEAN PUBLIC ASSESSMENT REPORT OF DRUGS ENOUGH? |
|
4CPS-284 |
TREATMENT OF CYCLIN INHIBITOR INDUCED NEUTROPENIA: IMPACT ON PROGRESSION FREE SURVIVAL |
|
4CPS-285 |
MULTIDISCIPLINARY ORAL THERAPY OUTPATIENT CLINIC: AN ITALIAN SINGLE CENTRE EXPERIENCE |
|
4CPS-286 |
EARLY IMPACT OF COVID ON THE ACTIVITY OF A CLINICAL RESEARCH ONCOLOGY PHARMACY UNIT AT A TERTIARY CARE HOSPITAL |
|
4CPS-287 |
IMPACT OF SARS-COV-2 INFECTION IN ACUTE MYELOID LEUKAEMIA PATIENTS: EXPERIENCE OF THE PETHEMA REGISTRY |
|
4CPS-288 |
CLINICAL PHARMACIST'S IMPACT IN IMPROVING THE SAFETY OF THERAPIES FOR PATIENTS USING ORAL ANTICANCER AGENTS: A PROSPECTIVE SINGLE CENTRE STUDY |
|
4CPS-289 |
ANALYSIS OF ANTINEOPLASTIC DRUG CONTAMINATION LEVEL IN THE HOSPITAL PHARMACY: PROBLEM MONITORING AND SOLVING |
|
4CPS-290 |
BORTEZOMIB INDUCED ACUTE NECROHAEMORRHAGIC PANCREATITIS: A CASE REPORT |
|
4CPS-291 |
PALBOCICLIB: EARLY NEUTROPENIA AS A PHARMACODYNAMIC MARKER IN A REAL WORLD SETTING? |
|
4CPS-292 |
EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHATIC LEUKAEMIA: MULTICENTRE STUDY |
|
4CPS-293 |
EFFICACY AND SAFETY OF CYCLIN DEPENDENT KINASE INHIBITORS IN METASTATIC BREAST CANCER |
|
4CPS-294 |
EFFICACY AND SAFETY PROFILE OF TRIFLURIDINE TIPIRACIL AND REGORAFENIB IN THE TREATMENT OF METASTATIC COLORECTAL CANCER |
|
4CPS-295 |
IMMUNOTHERAPY FOR CANCER THERAPEUTIC POSITIONING REPORTS: KNOWLEDGE, EXPECTATIONS AND EXPERIENCES THROUGH A NATIONAL SURVEY. |
|
4CPS-296 |
IMPACT OF THE COVID-19 PANDEMIC ON CLINICAL LUNG CANCER MANAGEMENT |
|
4CPS-297 |
SPINAL CORD APLASIA CAUSED BY 6-MERCAPTOPURINE IN A CAUCASIAN GIRL WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND HOMOZYGOUS MUTATION IN NUDIX HYDROLASE 15: CASE REPORT |
|
4CPS-298 |
EFFICACY AND SAFETY PROFILE OF ANTI-EGFR TYROSINE KINASE INHIBITOR THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER |
|
4CPS-299 |
PATIENTS’ MISCONCEPTIONS FOLLOWING INITIATION OF ANTINEOPLASTIC TREATMENT FOR COLORECTAL CANCER |
|
4CPS-300 |
EFFECTIVENESS AND SAFETY OF CEMIPLIMAB IN SQUAMOUS CELL CARCINOMA OF THE SKIN IN A THIRD LEVEL HOSPITAL |
|
4CPS-301 |
ASSOCIATION OF ANTIBIOTICS AND PROTON PUMP INHIBITORS ON CLINICAL ACTIVITY OF FIRSTLINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER: 2 YEARS OF REAL WORLD DATA |
|
4CPS-302 |
SORAFENIB IN HEPATOCARCINOMA: RESULTS IN A REAL WORLD SETTING |
|
4CPS-303 |
EFFICACY AND SAFETY OF MONOTHERAPY WITH PEMBROLIZUMAB IN NON-MICROCYTIC METASTATIC LUNG CANCER IN CLINICAL PRACTICE. |
|
4CPS-304 |
RITUXIMAB AS AN ALTERNATIVE IN NEUROLOGIC DISORDERS: LONG TERM STUDY |
|
4CPS-305 |
EFFECTIVENESS AND SAFETY OF BRAF/MEK INHIBITORS IN ADVANCED OR METASTATIC MELANOMA IN TWO TERTIARY HOSPITALS |
|
4CPS-306 |
DAROLUTAMIDE, ENZALUTAMIDE AND APALUTAMIDE: PLACE IN THERAPEUTICS OF CASTRATION RESISTANT NON METASTATIC PROSTATE CANCER |
|
4CPS-307 |
SAFETY EVALUATION OF NEW ANTIANDROGENIC DRUGS IN CASTRATION RESISTANT NON-METASTATIC PROSTATE CANCER |
|
4CPS-308 |
EXPERIENCE WITH TERIFLUNOMIDE TREATMENT FOR MULTIPLE SCLEROSIS IN A UNIVERSITY HOSPITAL |
|
4CPS-309 |
BARRIERS TO ADHERENCE WITH PRESCRIBED TREATMENTS IN MULTIPLE SCLEROSIS PATIENTS |
|
4CPS-310 |
TOFACITINIB EFFECTIVENESS AND SAFETY RESULTS: REAL WORLD DATA |
|
4CPS-311 |
REAL WORLD TOXICITY AND MANAGEMENT OF CHIMERIC ANTIGEN RECEPTOR T CELL THERAPIES TARGETING CD19 IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES |
|
4CPS-312 |
PHARMACEUTICAL INTERVENTIONS IN A NON-ONCOHAEMATOLOGICAL DAILY HOSPITAL |
|
4CPS-313 |
EXPERIENCE OF THE USE OF BARICITINIB IN COVID-19 PNEUMONIA |
|
4CPS-314 |
3 DAY COURSE OF LOW DOSE SUBCUTANEOUS ANAKINRA IN PATIENTS WITH REFRACTORY MODERATE-SEVERE COVID-19: A PROOF-OF-CONCEPT STUDY |
|
4CPS-315 |
EVALUATION OF THE EFFECTIVENESS OF EARLY ADMINISTRATION OF TOCILIZUMAB IN PATIENTS WITH COVID-19 |
|
4CPS-316 |
MULTIPLE SCLEROSIS OUTPATIENT PHARMACEUTICAL CARE BY AN IMPLANTED TELEPHARMACY TOOL DURING SARS-COV-2 PANDEMIC |
|
4CPS-317 |
IMMUNOSUPPRESSIVE TREATMENT MANAGEMENT IN A COHORT OF HOSPITALIZED SOLID ORGAN RECIPIENTS AFFECTED BY COVID-19 |
|
4CPS-318 |
COMPOUNDING TACROLIMUS OPHTHALMIC OINTMENT 0,02% IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE OPHTHALMIC SYNDROMES: EFFECTIVENESS AND SAFETY ASSESSMENT |
|
4CPS-319 |
PIRFENIDONE AND NINTEDANIB FOR THE TREATMENT OF THE IDIOPATHIC PULMONARY FIBROSIS: AN ITALIAN HOSPITAL EXPERIENCE |
|
4CPS-320 |
IMPROVING MEDICATION ADHERENCE AND PATIENTS’ EXPERIENCE AFTER HEART TRANSPLANT USING A MULTILEVEL eHEALTH INTERVENTION: THE mHEART CLINICAL TRIAL |
|
4CPS-321 |
ANAKINRA IN SEVERE COVID-19 PNEUMONIA: RETROSPECTIVE STUDY |
|
4CPS-322 |
ADALIMUMAB CONCENTRATIONS PRIOR TO THE IMPLEMENTATION OF THERAPEUTIC DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE |
|
4CPS-323 |
EVALUATION OF THE USE, ADHERENCE AND TOLERANCE OF 0.03% TACROLIMUS EYE DROPS |
|
4CPS-324 |
EFFECTIVENESS AND SAFETY OF IXEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS |
|
4CPS-325 |
EFFECTS ON ADHERENCE IN PATIENTS WITH ARTHROPATHIES CHANGING TREATMENT |
|
4CPS-326 |
ADALIMUMAB’S PERSISTENCE IN RHEUMATHOLOGICAL DISEASES |
|
4CPS-327 |
EFFECTIVENESS, SAFETY AND ADHERENCE OF BARICITINIB AND TOFACITINIB IN RHEUMATOID ARTHRITIS |
|
4CPS-328 |
BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS ACCORDING TO THE MECHANISM OF ACTION |
|
4CPS-329 |
DO PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES THINK THEY KNOW THEIR MEDICATION? |
|
4CPS-330 |
INDIVIDUALISING THERAPIES THROUGH PHARMACOKINETICS: ADALIMUMAB FOR INFLAMMATORY BOWEL DISEASE |
|
4CPS-331 |
MMATORY PARAMETERS ANALYSIS IN SEVERE COVID-19 PATIENTS TREATED WITH TOCILIZUMAB |
|
4CPS-332 |
TOCILIZUMAB FOR TREATING COVID PNEUMONIA: ANALYSIS OF EFFECTIVENESS AND SECURITY |
|
4CPS-333 |
TREATING MULTIPLE SCLEROSIS PATIENTS WITH INFUSION OF DISEASE MODIFYING TREATMENTS DRUGS DURING THE COVID-19 PANDEMIC |
|
4CPS-334 |
INFLUENCE OF ANTHROPOMETRIC, DEMOGRAPHIC AND THERAPEUTIC FACTORS ON SERUM CONCENTRATIONS OF ANTI-TNF DRUGS |
|
4CPS-335 |
EXPERIENCE IN THE USE OF TOCILIZUMAB IN PATIENTS WITH COVID-19. HAS IT REALLY BEEN EFFECTIVE? |
|
4CPS-336 |
IMPACT OF CHECK OF MEDICATION APPROPRIATENESS (CMA) IN OPTIMISING ANALGESIC PRESCRIBING |
|
4CPS-337 |
PERSISTENCE OF BIOSIMILAR TREATMENT FOR IMMUNE MEDIATED INFLAMMATORY DISEASES IN CLINICAL PRACTICE |
|
4CPS-338 |
USE AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA |
|
4CPS-339 |
INTRATHECAL ADMINISTRATION OF BACLOFEN FOR THE REDUCTION OF SPASTICITY |
|
4CPS-340 |
PROFILE OF PATIENTS WITH ABUSIVE CONSUMPTION OF QUICK RELEASE FENTANYL IN A HEALTHCARE AREA |
|
4CPS-341 |
THE ROLE OF PHARMACISTS IN PROVIDING PHARMACEUTICAL CARE FOR PATIENTS WITH HEADACHES |
|
4CPS-342 |
TRANSIENT VALPROIC ACID TOXICITY: HYPERAMMONAEMIA IN A PAEDIATRIC PATIENT |
|
4CPS-343 |
PREGABALIN AND GABAPENTIN DRUG UTILISATION REVIEW |
|
4CPS-344 |
PRESCRIPTION AUDITING OF THE 3 MONTHLY FORMULATION OF PALIPERIDONE PALMITATE IN ADULT PATIENTS WITH SCHIZOPHRENIA |
|
4CPS-345 |
MANAGEMENT OF BRONCHIOLITIS IN HOSPITALISED CHILDREN |
|
4CPS-346 |
EVALUATION OF THE IMPLEMENTATION OF "INHALER INTERVIEWS" DURING MEDICATION RECONCILIATION IN THE PNEUMOLOGY SERVICE |
|
4CPS-347 |
CLINICAL TRIAL DRUGS: DISPENSING OPTIMISATION FOR OUTPATIENTS OF A CANCER CENTRE |
|
4CPS-348 |
THE HOSPITAL PHARMACY IN THE CREATION OF CLEAN CIRCUITS IN THE FACE OF COVID-19 |
|
4CPS-349 |
ROLE OF HOSPITAL PHARMACISTS IN ONCOGERIATRIC CONSULTATIONS: A RETROSPECTIVE STUDY |
|
4CPS-350 |
ROLE OF THE PHARMACIST IN INTERNAL MEDICINE: ANALYSIS OF PHARMACEUTICAL INTERVENTIONS DURING A ROTATION IN AN INTERNAL MEDICINE DEPARTMENT |
|
4CPS-351 |
MEDICATION DELIVERY CONFIRMATION TO AMBULATORY PATIENTS BY INSTANT MESSAGING APP |
|
4CPS-352 |
PATIENTS IN CHARGE: WHY WE SHOULD IMPLEMENT AN ONLINE PERSONAL HEALTH RECORD AS A TOOL FOR MEDICATION RECONCILIATION |
|
4CPS-353 |
COLLABORATION BETWEEN HOSPITAL AND COMMUNITY PHARMACISTS ABOUT DISCHARGED PATIENTS: A PILOT STUDY |
|
4CPS-354 |
EFFICACY AND SAFETY WITH ERENUMAB AND GALCANEZUMAB: OUR EXPERIENCE |
|
4CPS-355 |
EVALUATION OF PATIENTS CONSULTING THE EMERGENCY DEPARTMENT FOR BRADYCARDIA RELATED TO MEDICATION |
|
4CPS-356 |
COST-MINIMISATION ANALYSIS OF THE USE OF NIVOLUMAB AND PEMBROLIZUMAB |
|
4CPS-357 |
CLINICAL CHARACTERISTICS AND MORTALITY OF COVID-19 IN A LONG TERM CARE FACILITY |
|
4CPS-358 |
POINT PREVALENCE REVIEW OF MEDICINES RECONCILIATION FOLLOW-UP BY MEDICAL TEAMS |
|
4CPS-359 |
DEVELOPMENT AND VALIDATION OF A 30 DAY REVISIT RISK PREDICTION MODEL IN PATIENTS ADMITTED TO THE EMERGENCY DEPARTMENT DUE TO DRUG RELATED PROBLEMS |
|
4CPS-360 |
RISK OF MALNUTRITION IN PATIENTS WITH COVID-19 DISEASE WHO RECEIVE ORAL NUTRITIONAL SUPPLEMENTS |
|
4CPS-361 |
INTERVENTIONS OF A CLINICAL PHARMACIST IN AN INTENSIVE CARE UNIT |
|
4CPS-362 |
NONAGENARIANS VERSUS NON-NONAGENARIANS IN THE HIP FRACTURE PATIENT: FROM A PHARMACOTHERAPEUTIC POINT OF VIEW |
|
4CPS-363 |
DOES PATIENT CENTRED CARE PRACTICE IMPROVE MEDICATION ADHERENCE OF PATIENTS WITH TYPE 2 DIABETES MELLITUS? |
|
4CPS-364 |
PERSONALISED QT RISK ASSESSMENT - TO INFORM MEDICATION PRESCRIBING? |
|
4CPS-365 |
INTEGRATION OF THE HOSPITAL PHARMACIST INTO A MULTIDISCIPLINARY COMPLEX CHRONIC PATIENT CARE TEAM |
|
4CPS-366 |
COMPARING THE MEDICATION PROCESS ACROSS COUNTRIES USING THE FUNCTIONAL RESONANCE ANALYSIS METHOD |
|
4CPS-367 |
IMPACT OF PHARMACEUTICAL CONSULTATION IMPLEMENTATION ON THE PHARMACEUTICAL INTERVENTIONS AND THE ROLE OF PHARMACISTS IN MULTIDISCIPLINARY TEAMS |
|
4CPS-368 |
SYSTEMATIC REVIEW OF THE ASSOCIATION BETWEEN ANTICHOLINERGIC BURDEN AND XEROSTOMIA AND XEROPHTHALMIA |
|
4CPS-369 |
PHARMACHECK AS A SCREENING TOOL TO INTERCEPT HIGH RISK SITUATIONS IN INTERNAL MEDICINE THAT COULD LEAD TO ADVERSE DRUG EVENTS |
|
4CPS-370 |
PHARMACISTS´ INTERVENTIONS BEFORE AND AFTER THE USE OF A CLINICAL DECISION SUPPORT TOOL TO DETECT DRUG RELATED PROBLEMS |
|
4CPS-371 |
USABILITY EVALUATION OF A PERSONALISED HEALTH RECORD FOR DETECTING MEDICATION DISCREPANCIES |
|
4CPS-372 |
PHARMACEUTICAL INTERVENTIONS IN HOSPITALIZED PATIENTS DURING THE FIRST WAVE OF SARS-COV-2 PANDEMIC |
|
4CPS-373 |
PHARMACEUTICAL CARE IN HOSPITALISATION UNITS: ANALYSIS OF INTERVENTIONS |
|
4CPS-374 |
A SCREENING MODEL TO IDENTIFY ELDERLY POLYPHARMACY PATIENTS THAT MAY BENEFIT FROM PHARMACIST LED MEDICATION REVIEW DURING HOSPITAL ADMISSION |
|
4CPS-375 |
EXCESSIVE POLYPHARMACY AND OTHER DETERMINANTS FOR UNPLANNED HOSPITAL ADMISSIONS |
|
4CPS-376 |
ANTIRETROVIRAL THERAPY OPTIMISATION STRATEGIES IN PATIENTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS: A DECISIVE TASK FOR HOSPITAL PHARMACISTS |
|
4CPS-377 |
APPROPRIATENESS OF NUTRITIONAL SUPPORT FOR PATIENTS WITH INVASIVE MECHANICAL VENTILATION WITH COVID-19 DISEASE REQUIRING INTENSIVE CARE |
|
4CPS-378 |
ORAL THERAPY ADHERENCE AND SATISFACTION IN PATIENTS WITH MULTIPLE MYELOMA |
|
4CPS-379 |
PARENTERAL NUTRITION MANAGEMENT IN CORONAVIRUS CRITICAL PATIENTS: CASE REPORT |
|
4CPS-380 |
AN INTEGRATED PHARMACIST LED MEDICATION REVIEW SERVICE FOR ELECTIVE SURGERY PATIENTS AT THE PRE-ANAESTHESIA OUTPATIENT CLINIC |
|
4CPS-381 |
PROACTIVE MEDICATION RECONCILIATION AND PATIENT FLOW IN THE EMERGENCY DEPARTMENT ADMISSIONS |
|
4CPS-382 |
IMPACT OF A CLINICAL PHARMACIST AT TRANSITION OF CARE: A PROSPECTIVE STUDY IN AN ORTHOPAEDIC WARD OF A REGIONAL HOSPITAL |
|
4CPS-383 |
DRUG PRESCRIPTION IN THE ELDERLY. ARE WE DOING WELL? |
|
4CPS-384 |
POTENTIAL DRUG-RELATED PROBLEMS IN THE TIME OF COVID-19 |
|
4CPS-385 |
IMPACT OF FULLY AUTOMATISED CENTRAL INTRAVENOUS ADDITIVE SERVICE (CIVAS) ON DAILY NURSING PRACTICE |
|
4CPS-386 |
ONE YEAR EXPERIENCE OF A NEW PROGRAMME OF TELEMATIC PHARMACEUTICAL CONSULTATION AND DELIVERY OF HOSPITAL DISPENSING MEDICATION |
|
4CPS-387 |
COVID-19 TREATMENT: A FOLLOW-UP OF INPATIENTS DURING THE SECOND WAVE OF THE PANDEMIC |
|
4CPS-388 |
TELEPHARMACY DURING SARS-COV-2 |
|
4CPS-389 |
GOVERNANCE OF CLINICAL TRIALS BETWEEN HEALTH NEEDS, ACCESS TO CARE, INNOVATION AND SUSTAINABILITY IN THE COVID-19 PANDEMIC ERA |
|
4CPS-390 |
DISPENSING OF ANTICANCER INVESTIGATIONAL DRUGS DURING THE LOCKDOWN FOR THE SARS-COV-2 PANDEMIC: EXPERIENCE IN AN ONCOLOGICAL CENTRE |
|
4CPS-391 |
NON-ADHERENCE IN RHEUMATOLOGICAL IMMUNE MEDIATED DISEASES |
|
4CPS-392 |
EFFECT OF COVID 19 PANDEMIC ON ANTIRETROVIRAL THERAPY ADHERENCE |
|
4CPS-393 |
IMPACT OF MULTIDISCIPLINARY TEAM INTERVENTION IN MEDICATION RECONCILIATION FOR GERIATRIC PATIENTS |
|
4CPS-394 |
EVALUATION OF THE DEGREE OF THERAPEUTIC KNOWLEDGE IN LUNG TRANSPLANT RECIPIENTS |
|
4CPS-395 |
PHARMACY SERVICE’S ADAPTATION TO THE COVID-19 PANDEMIC: TELEPHARMACY AND HOME DRUG DELIVERY |
|
4CPS-396 |
EFFECT OF PATIENT'S OWN MEDICATION USE ON PATIENT SELF-REPORTED MEDICATION KNOWLEDGE DURING HOSPITALISATION: A PRE-POST INTERVENTION STUDY |
|
4CPS-397 |
ASSESSMENT OF PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT AFTER COMPUTERISED PHYSICIAN ORDER ENTRY SYSTEM IMPLEMENTATION |
|
4CPS-398 |
USE OF INTRAVENOUS IRON IN HEART FAILURE OCTOGENARIANS AND NONAGENARIANS WITH IRON DEFICIENCY |
|
4CPS-399 |
EVALUATING CLINICAL PHARMACY SERVICES ON AN INTENSIVE CARE UNIT: A SATISFACTION SURVEY |
|
4CPS-400 |
THE ROLE AND VALUE OF A WARD BASED PHARMACIST IN THE INTENSIVE CARE UNIT: THE CRITICAL CARE PHYSICIANS’ AND NURSES’ PERCEPTIONS |
|
4CPS-401 |
TELEPHARMACY PROGRAMME IMPLEMENTATION DURING THE COVID-19 PANDEMIC |
|
4CPS-402 |
COVID-19 AND DIGESTIVE SURGERY: MEDICAL DEVICES FOR SURGICAL SMOKE FILTRATION |
|
4CPS-403 |
CHRONIC KIDNEY DISEASE (CKD) PATIENTS AND POLYPHARMACY: HOW TO OPTIMISE AND SIMPLIFY PRESCRIPTIONS? |
|
4CPS-404 |
MULTIDISCIPLINARY TEAM AIMED TO OPTIMISE INDIVIDUALISED SPECIAL DRUGS PRESCRIPTIONS AND AUTHORISATION BY HOSPITAL MEDICAL DIRECTOR THROUGH AN INFORMATIC APPLICATION |
|
4CPS-405 |
STRONGYLOIDES STERCORALIS PROPHYLAXIS WITH IVERMECTIN IN COVID-19 PATIENTS |